2024/12/12 by Rahmah S. Alzahrani, Donald C. Vinh, Ewa Rajda +3 · 1 voice
Medicine · #Fungal Infections and Studies #Antifungal resistance and susceptibility #Nail Diseases and Treatments
paper · doi:10.1128/asmcr.00045-24
openalex publication_date 2024/12/12 · openalex created_date 2024/12/13 · openalex updated_date 2026/08/01
Background: ) is a yeast with a filamentous form, as well as an uncommon, yet emerging opportunistic pathogen. It occurs primarily in patients experiencing prolonged neutropenia, and there is limited evidence available to guide antifungal agent selection and treatment decisions. Case Summary: in a patient with myelofibrosis following allogeneic hematopoietic stem cell transplantation. The patient was treated with voriconazole, as well as liposomal amphotericin B, along with granulocyte transfusion. The patient died from persistent fungemia, refractory septic shock, and multiorgan failure 20 days after the infection was first diagnosed. Conclusion: We subsequently discuss the epidemiological, clinical, and therapeutic features of this severe fungal infection and present a review of currently available literature.